Publications
  1.  Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial. Katz MHG, Shi Q, Meyers J, Herman JM, Chuong M, Wolpin BM, Ahmad S, Marsh R, Schwartz L, Behr S, Frankel WL, Collisson E, Leenstra J, Williams TM, Vaccaro G, Venook A, Meyerhardt JA, O'Reilly EM.JAMA Oncol. 2022 Sep 1;8(9):1263-1270. doi: 10.1001/jamaoncol.2022.2319.PMID: 35834226
  2. Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes.

    Reggiardo RE, Maroli SV, Halasz H, Ozen M, Hrabeta-Robinson E, Behera A, Peddu V, Carrillo D, LaMontagne E, Whitehead L, Kim E, Malik S, Fernandes J, Marinov G, Collisson E, Brooks A, Demirci U, Kim DH.Cell Rep. 2022 Jul 19;40(3):111104. doi: 10.1016/j.celrep.2022.111104.PMID: 35858545.

  3. Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.

    Jiang H, Muir RK, Gonciarz RL, Olshen AB, Yeh I, Hann BC, Zhao N, Wang YH, Behr SC, Korkola JE, Evans MJ, Collisson EA, Renslo AR.J Exp Med. 2022 Apr 4;219(4):e20210739. doi: 10.1084/jem.20210739. Epub 2022 Mar 9.PMID: 35262628.

  4. Hendley AM, Rao AA, Leonhardt L, Ashe S, Smith JA, Giacometti S, Peng XL, Jiang H, Berrios DI, Pawlak M, Li LY, Lee J, Collisson EA, Anderson MS, Fragiadakis GK, Yeh JJ, Ye CJ, Kim GE, Weaver VM, Hebrok M. Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree. Elife. 2021 May 19;10:e67776. doi: 10.7554/eLife.67776.
    PMID: 34009124 
  5. Carrot-Zhang J, Yao X, Devarakonda S, Deshpande A, Damrauer JS, Silva TC, Wong CK, Choi HY, Felau I, Robertson AG, Castro MAA, Bao L, Rheinbay E, Liu EM, Trieu T, Haan D, Yau C, Hinoue T, Liu Y, Shapira O, Kumar K, Mungall KL, Zhang H, Lee JJ, Berger A, Gao GF, Zhitomirsky B, Liang WW, Zhou M, Moorthi S, Berger AH, Collisson EA, Zody MC, Ding L, Cherniack AD, Getz G, Elemento O, Benz CC, Stuart J, Zenklusen JC, Beroukhim R, Chang JC, Campbell JD, Hayes DN, Yang L, Laird PW, Weinstein JN, Kwiatkowski DJ, Tsao MS, Travis WD, Khurana E, Berman BP, Hoadley KA, Robine N; TCGA Research Network, Meyerson M, Govindan R, Imielinski M. Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway. Cell Rep. 2021 Feb 2;34(5):108707. doi: 10.1016/j.celrep.2021.108707.PMID: 33535033 
  6. Audrey M. Hendley, Arjun A. Rao, Laura Leonhardt, Sudipta Ashe, Jennifer A. Smith, Simone Giacometti, Xianlu L Peng, Honglin Jiang, David I. Berrios, Mathias Pawlak, Lucia Y. Li, Jonghyun Lee, Eric A. Collisson, Mark Anderson, Gabriela K. Fragiadakis, Jen Jen Yeh, Jimmie Ye Chun, Grace E. Kim, Valerie M. Weaver, Matthias HebrokSingle cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree. https://doi.org/10.1101/2020.10.12.336784
  7. Honglin Jiang,1 Robert J. Torphy,2 Katja Steiger,3 Henry Hongo,1 Alexa J. Ritchie,1 Mark Kriegsmann,4 David Horst,5 Sarah E. Umetsu,6 Nancy M. Joseph,6 Kimberly McGregor,7 Michael J. Pishvaian,8,9,10 Edik M. Blais,10 Brian Lu,11 Mingyu Li,11 Michael Hollingsworth,12 Connor Stashko,13 Keith Volmar,14 Jen Jen Yeh,15,16,17 Valerie M. Weaver,13 Zhen J. Wang,18 Margaret A. Tempero,1 Wilko Weichert,3 and Eric A. Collisson1. Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix. J Clin Invest. 2020;130(9):4704-4709. https://doi.org/10.1172/JCI136760
  8. Wang MT, Fer N, Galeas J, Collisson EA, Kim SE, Sharib J, McCormick F. Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer. Nat Commun. 2019 Jul 11; 10(1):3055.
    View on PubMed
  9. Shi Y, Gao W, Lytle NK, Huang P, Yuan X, Dann AM, Ridinger-Saison M, DelGiorno KE, Antal CE, Liang G, Atkins AR, Erikson G, Sun H, Meisenhelder J, Terenziani E, Woo G, Fang L, Santisakultarm TP, Manor U, Xu R, Becerra CR, Borazanci E, Von Hoff DD, Grandgenett PM, Hollingsworth MA, Leblanc M, Umetsu SE, Collisson EA, Scadeng M, Lowy AM, Donahue TR, Reya T, Downes M, Evans RM, Wahl GM, Pawson T, Tian R, Hunter T. Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring. Nature. 2019 05; 569(7754):131-135.
    View on PubMed
  10. Collisson EA, Bailey P, Chang DK, Biankin AV. Molecular subtypes of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2019 Apr; 16(4):207-220.
    View on PubMed
  11. Walker EJ, Carnevale J, Pedley C, Blanco A, Chan S, Collisson EA, Tempero MA, Ko AH. Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma. Fam Cancer. 2019 Apr; 18(2):241-251.
    View on PubMed
  12. Collisson EA. Bringing Pancreas Cancer into the Lab. Cancer Discov. 2018 Sep; 8(9):1062-1063.
    View on PubMed
  13. Cho RJ, Alexandrov LB, den Breems NY, Atanasova VS, Farshchian M, Purdom E, Nguyen TN, Coarfa C, Rajapakshe K, Prisco M, Sahu J, Tassone P, Greenawalt EJ, Collisson EA, Wu W, Yao H, Su X, Guttmann-Gruber C, Hofbauer JP, Hashmi R, Fuentes I, Benz SC, Golovato J, Ehli EA, Davis CM, Davies GE, Covington KR, Murrell DF, Salas-Alanis JC, Palisson F, Bruckner AL, Robinson W, Has C, Bruckner-Tuderman L, Titeux M, Jonkman MF, Rashidghamat E, Lwin SM, Mellerio JE, McGrath JA, Bauer JW, Hovnanian A, Tsai KY, South AP. APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa. Sci Transl Med. 2018 Aug 22; 10(455).
    View on PubMed
  14. Wang ZJ, Behr S, Consunji MV, Yeh BM, Ohliger MA, Gao K, Ko AH, Cinar P, Tempero MA, Collisson EA. Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI. AJR Am J Roentgenol. 2018 Nov; 211(5):1010-1019.
    View on PubMed
  15. Jha P, Yeh BM, Zagoria R, Collisson E, Wang ZJ. The Role of MR Imaging in Pancreatic Cancer. Magn Reson Imaging Clin N Am. 2018 Aug; 26(3):363-373.
    View on PubMed
  16. North JP, Golovato J, Vaske CJ, Sanborn JZ, Nguyen A, Wu W, Goode B, Stevers M, McMullen K, Perez White BE, Collisson EA, Bloomer M, Solomon DA, Benz SC, Cho RJ. Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma. Nat Commun. 2018 05 14; 9(1):1894.
    View on PubMed
  17. Lim HC, Montesion M, Botton T, Collisson EA, Umetsu SE, Behr SC, Gordan JD, Stephens PJ, Kelley RK. Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in BRCA1-Mutant Cholangiocarcinoma Harboring a Novel YWHAZ-BRAF Fusion. Oncologist. 2018 Sep; 23(9):998-1003.
    View on PubMed
  18. Torphy RJ, Wang Z, True-Yasaki A, Volmar KE, Rashid N, Yeh B, Anderson JM, Johansen JS, Hollingsworth MA, Yeh JJ, Collisson EA. Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma. JCO Precis Oncol. 2018; 2018.
    View on PubMed
  19. Aguirre AJ, Collisson EA. Advances in the Genetics and Biology of Pancreatic Cancer. Cancer J. 2017 Nov/Dec; 23(6):315-320.
    View on PubMed
  20. Chen I, Raymond VM, Geis JA, Collisson EA, Jensen BV, Hermann KL, Erlander MG, Tempero M, Johansen JS. Ultrasensitive plasma ctDNA KRAS assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma. Oncotarget. 2017 Nov 17; 8(58):97769-97786.
    View on PubMed
  21. Korkola JE, Collisson EA, Heiser LM, Oates C, Bayani N, Itani S, Esch A, Thompson W, Griffith OL, Wang NJ, Kuo WL, Cooper B, Billig J, Ziyad S, Hung JL, Jakkula L, Feiler H, Lu Y, Mills GB, Spellman PT, Tomlin C, Mukherjee S, Gray JW. Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer. PLoS One. 2017; 12(10):e0186551.
    View on PubMed
  22. Katz MHG, Ou FS, Herman JM, Ahmad SA, Wolpin B, Marsh R, Behr S, Shi Q, Chuong M, Schwartz LH, Frankel W, Collisson E, Koay EJ, Hubbard JM, Leenstra JL, Meyerhardt J, O'Reilly E. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas. BMC Cancer. 2017 Jul 27; 17(1):505.
    View on PubMed
  23. Lu X, Peled N, Greer J, Wu W, Choi P, Berger AH, Wong S, Jen KY, Seo Y, Hann B, Brooks A, Meyerson M, Collisson EA. MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma. Cancer Res. 2017 08 15; 77(16):4498-4505.
    View on PubMed
  24. Collisson EA, Maitra A. Pancreatic Cancer Genomics 2.0: Profiling Metastases. Cancer Cell. 2017 03 13; 31(3):309-310.
    View on PubMed

Grants

  1. NIH/NCIR01 - Optimizing Pancreatic Cancer Management with Next Genera
  2. NIH/NCIR01 - Understanding Efficacy and Fe(II)-Promoted Activation of
  3. NIH/NCIR01 - Genomics and Functional Characterization of NF1-mutated Lung Cancer
  4. NIH/NICR01 - Tailoring Therapy to Pancreatic Cancer Subtypes
  5. NIH/NCI Optimizing Treatment Approaches to Lung Cancers Harboring MET Exon 14 mutations
  6. NIH/NCI (Dr. Jura's R01) The structural and functional basis of MET exon 14 activation and acquired drug resistance